Norfloxacin
FDA-approved product (tablet, oral), marketed as Chibroxin, Noroxin.
- Registered studies
- 30
- Lab records
- 179
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Eye infection
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Fluoroquinolones
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01MA06; WHO ATC S01AE02
Repurposing investigation
Norfloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA93.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae92.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
30registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 45 of 47 lab records
- E. coli: measured active in 51 of 52 lab records
- K. pneumoniae: measured active in 65 of 80 lab records
Show the latest 150 of 179 laboratory records, with sources
Loading records…
Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Norfloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)
NCT06199843 · start 2024-01-05
Registered record
- Registry ID
- NCT06199843
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- Rifaximin; Norfloxacin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2024-01-05
- Completion
- 2024-12-31
- Enrolment
- 280
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial PeritonitisInterventionRifaximin; NorfloxacinPhaseNot applicableRegistry statusUnknownAn Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions
NCT05667818 · start 2023-01-28
Registered record
- Registry ID
- NCT05667818
- Conditions
- Hypertension
- Interventions
- Amlodipine besylate tablets (trade name: Norfloxacin ®); Amlodipine besylate controlled-release tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2023-01-28
- Completion
- 2023-03-10
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionAmlodipine besylate tablets (trade name: Norfloxacin ®); Amlodipine besylate controlled-release tabletsPhasePhase 1Registry statusUnknownComparative Study of Secondary Prophylaxis for SBP
NCT06827756 · start 2021-03-01
Registered record
- Registry ID
- NCT06827756
- Conditions
- Spontaneous Bacterial Peritonitis; Cirrhoses, Liver; Ascites
- Interventions
- Norfloxacin 400 MG; Nitazoxanide 500 MG; Colistin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-03-01
- Completion
- 2022-02-01
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial Peritonitis; Cirrhoses, Liver; AscitesInterventionNorfloxacin 400 MG; Nitazoxanide 500 MG; ColistinPhasePhase 4Registry statusCompletedNitazoxanide in Prevention of Secondary Spontaneous Peritonitis
NCT04746937 · start 2021-03
Registered record
- Registry ID
- NCT04746937
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- Nitazoxanide; Norfloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2021-03
- Completion
- 2022-05
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial PeritonitisInterventionNitazoxanide; NorfloxacinPhasePhase 3Registry statusUnknownMidodrine and Albumin in Patients With Refractory Ascites
NCT04621617 · start 2020-11
Registered record
- Registry ID
- NCT04621617
- Conditions
- Refractory Ascites
- Interventions
- Albumin; Midodrine; Standard medical therapy (SMT)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2020-11
- Completion
- 2022-04
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRefractory AscitesInterventionAlbumin; Midodrine; Standard medical therapy (SMT)PhasePhase 3Registry statusUnknownRifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
NCT04159870 · start 2019-11-05
Registered record
- Registry ID
- NCT04159870
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- Rifaximin; Norfloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2019-11-05
- Completion
- 2021-12-20
- Enrolment
- 322
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial PeritonitisInterventionRifaximin; NorfloxacinPhasePhase 3Registry statusUnknownAntibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan
NCT05106803 · start 2019-08-01
Registered record
- Registry ID
- NCT05106803
- Conditions
- Bacterial Infections; Antibiotic Resistant Infection; Surgical Site Infection
- Interventions
- ciprofloxacin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2019-08-01
- Completion
- 2019-10-01
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections; Antibiotic Resistant Infection; Surgical Site InfectionInterventionciprofloxacinPhaseNot recordedRegistry statusCompletedRifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients
NCT05621005 · start 2019-03-01
Registered record
- Registry ID
- NCT05621005
- Conditions
- Ascites Infection
- Interventions
- Rifaximin 550 milligram Oral Tablet [XIFAXAN]
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2019-03-01
- Completion
- 2022-08-01
- Enrolment
- 104
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAscites InfectionInterventionRifaximin 550 milligram Oral Tablet [XIFAXAN]PhasePhase 2Registry statusCompletedNorfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
NCT04161768 · start 2018-12-01
Registered record
- Registry ID
- NCT04161768
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- Norfloxacin; Itopride
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2018-12-01
- Completion
- 2028-12-01
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial PeritonitisInterventionNorfloxacin; ItopridePhasePhase 3Registry statusRecruitingMedication Adherence in Patients With Liver Cirrhosis
NCT03627338 · start 2018-09-01
Registered record
- Registry ID
- NCT03627338
- Conditions
- Medication Adherence
- Interventions
- questionaire, interview
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2018-09-01
- Completion
- 2021-05-31
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMedication AdherenceInterventionquestionaire, interviewPhaseNot recordedRegistry statusUnknownComparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis
NCT03702426 · start 2018-07-23
Registered record
- Registry ID
- NCT03702426
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- GMCSF; Norfloxacin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2018-07-23
- Completion
- 2019-07-31
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpontaneous Bacterial PeritonitisInterventionGMCSF; NorfloxacinPhaseNot applicableRegistry statusCompletedNoroxin Efficacy and Safety Trial
NCT03506256 · start 2018-05-10
Registered record
- Registry ID
- NCT03506256
- Conditions
- Urinary Tract Infections
- Interventions
- Norfloxacin 400 MG
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2018-05-10
- Completion
- 2018-07-30
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary Tract InfectionsInterventionNorfloxacin 400 MGPhasePhase 4Registry statusUnknownA Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
NCT03479736 · start 2017-11-20
Registered record
- Registry ID
- NCT03479736
- Conditions
- Retinal Detachment; Achilles Tendon; Aneurysm, Dissecting
- Interventions
- Oral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2017-11-20
- Completion
- 2018-06-04
- Enrolment
- 117,911
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRetinal Detachment; Achilles Tendon; Aneurysm, DissectingInterventionOral Fluoroquinolones (FQ); Other Antibiotics; Febrile Illness Not Treated with Antibiotics Will be Analyzed as an ExposurePhaseNot recordedRegistry statusCompletedRifaximin and Norfloxacin for Prevention of SBP in Adults With Decompensated Cirrhosis
NCT03695705 · start 2016-01-01
Registered record
- Registry ID
- NCT03695705
- Conditions
- Cirrhosis, Liver
- Interventions
- Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-01-01
- Completion
- 2017-06-30
- Enrolment
- 142
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCirrhosis, LiverInterventionRifaximin 550 mg twice a day and Norfloxacin 400 mg once a dayPhasePhase 3Registry statusCompletedPatients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminated